The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors

Objective: Refractory or recurrent pediatric solid tumors lack effective treatments, and are associated with dismal outcomes. Hence, there is an urgent need for a novel therapeutic strategy. This study aimed to evaluate the efficacy and safety of anlotinib, a novel oral multi-kinase angiogenesis inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Suying, Hong, Ye, Chen, Huimou, Wu, Liuhong, Sun, Feifei, Wang, Juan, Zhu, Jia, Que, Yi, Zhang, Lian, Zhen, Zijun, Sun, Xiaofei, Huang, Junting, Zhang, Yizhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008584/
https://www.ncbi.nlm.nih.gov/pubmed/35431969
http://dx.doi.org/10.3389/fphar.2022.711704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008584/
https://www.ncbi.nlm.nih.gov/pubmed/35431969
http://dx.doi.org/10.3389/fphar.2022.711704

Ejemplares similares